Emmanuel J Favaloro/LinkedIn
Nov 15, 2025, 15:41
Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
Emmanuel J Favaloro, Editor in Chief of Seminars in Thrombosis and Hemostasis, shared a post on LinkedIn:
“Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing. This Commentary has just been released online, and is free to download from.”
Title: Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing
Authors: Deepa J. Arachchillage, Saravanan Vinayagam, Annie Parsons, Nilanthi Karawitage, Mike Laffan
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB
-
Sep 3, 2026, 17:24N. Mariana S. Vasquez: JAK2 Mutations The High-Yield Map of Myeloproliferative Neoplasms
-
Sep 3, 2026, 17:08Khusi Dhara: Why Women Need to Pay Attention to Iron
-
Sep 3, 2026, 16:54Ralf Ludwig։ Testing Human-Targeted Therapies in a Human Immune System
-
Sep 3, 2026, 16:35Mohsen Salimi: Non-Contrast Chest CT as a Biomarker for Mild-to-Moderate Anemia
-
Sep 3, 2026, 16:10Tanzeel Alamin Almahdi Gorashi: NLR as an Accessible Biomarker for Monitoring Pediatric Sickle Cell Anemia
-
Sep 3, 2026, 15:42Manuel De Jesus: Innovating Anemia Monitoring Through Biomedical Engineering and Digital Technology